MyPharmaGenes® Brain PGx
PHARMACOGENETICS: VARIABILITY IN DRUG RESPONSE
Genetics contributes to individual differences, not only in characteristics such as height or skin colour but also at the pharmacological level. Pharmacogenetics studies the relationship between genetic variability and how we respond to drugs. This information assists doctors in therapeutic management, which includes selecting active compounds and adjusting doses. The ultimate goal of this approach is to maximize therapeutic effects and minimize the risk of side effects.
MyPharmaGenes® Brain PGx is a comprehensive pharmacogenetic test for the definition of a personalized pharmacological plan. This test evaluates 68 drugs commonly used in Psychiatry and Neurology.
Psychiatry
Neurology
An interactive WebApp
MyPharmaGenes® Brain PGx is supported by an interactive WebApp where patients can:
- Manage their own drug portfolio;
- Register drugs that have triggered side effects;
- Have rapid access to which drugs may or may not be recommended for them;
- Find more specific information regarding the genes evaluated.
MyPharmaGenes® BRAIN PGx is indicated for:
- Patients who are starting new therapies;
- Patients who are not achieving therapeutic goals and/or experience moderate to severe adverse effects with the current therapy;
Why is it important to address Pharmacogenetics?
- Variability in drug response constitutes a major public health concern, accounting for 2.5–10.6% of all hospital admissions in the EU [1].
- More than 90% of the drugs are not effective for more than 50% of patients [2,3].
- Approximately 17% of patients are receiving a drug that triggers adverse reactions [4].
- Genetic variants affecting the absorption, distribution, metabolism, excretion, and toxicity of drugs explain around 20–30% of the variability in drug response between individuals [5].
What is analysed?
The MyPharmaGenes® Brain PGx test analyses genetic variants associated with the metabolism and response to certain drugs, scientifically validated and with proven clinical utility.
MyPharmaGenes® BRAIN PGx highlights:
- Coverage of 68 drugs;
- Evaluation of 20 genes and 70 genetic variants;
- Evaluation of CYP2D6 CNVs and hybrid structures.
With the evaluation of the patients’ genotypic profile is it possible to:
- Prescribe more adequate drug dosages;
- Evaluate the patient’s response to the treatment;
- Avoid/minimise adverse drug reactions;
- Select alternative agents, if necessary
And, consequently, offer better treatment to more patients.
Drugs evaluated by therapeutic areA
-
Amisulpride, Amitriptyline, Amoxapine, Amphetamine, Aripiprazole, Atomoxetine, Brexpiprazole, Bupropion, Caffeine, Citalopram, Clobazam, Clomipramine, Clozapine, Desipramine, Diazepam, Doxepin, Escitalopram, Flibanserin, Fluoxetine, Fluvoxamine, Haloperidol, Iloperidone, Imipramine, Lithium, Lorazepam, Maprotiline, Methylphenidate, Mianserin, Midazolam, Nefazodone, Nortriptyline, Olanzapine, Oxazepam, Paliperidone, Paroxetine, Perphenazine, Pimozide, Protriptyline, Quetiapine, Risperidone, Sertindole, Sertraline, Thioridazine, Tianeptine, Trimipramine, Venlafaxine, Vortioxetine, Zuclopenthixol
-
Brivaracetam, Carbamazepine, Deutetrabenazine, Donepezil, Eliglustat, Entacapone, Fosphenytoin, Galantamine, Lamotrigine, Meclizine, Modafinil, Oxcarbazepine, Phenobarbital, Phenytoin, Pitolisant, Siponimod, Tetrabenazine, Tolperisone, Valbenazine, Valproic Acid
Turnaround time
15 working days
Scientific Studies
[2] Steve Connor (2003) “Glaxo chief: Our drugs do not work on most patients”, Independent/UK, 8/12/2003.
[3] Spear, B.B., Heath-Chiozzi, M. & Huff, J., “Clinical Application of Pharmacogenetics”. Trends Mol Med 7.5 (2001):201-204.
[4] Böhm, R. & Cascorbi, I., “Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions”. Front Pharmacol 7 (2016): 396.
[5] Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments”. AAPS J 20.1 (2018): 4.
[6] Gaedigk, Andrea, et al. “Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project”. J Mol Diagn 21.6 (2019): 1034-1052.